Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Complement Activation in a Murine Model of Sickle Cell Disease: Inhibition of Vaso-Occlusion By Blocking C5 Activation

Terry Robert Schaid, Jr., BA, Julia Nguyen, BS, Chunsheng Chen, PhD, Fuad Abdulla, DVM, Trevor Killeen, Hao Nguyen, Joseph Edmund, MBBS, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD, Agustin P Dalmasso, MD, John D Belcher, PhD, Gregory M Vercellotti, MD

Blood (2016) 128 (22): 158.

https://doi.org/10.1182/blood.V128.22.158.158

Published: 2016

Journal Articles

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

Federico V Grossi, MDPhD, Pauline Bedwell, Pascal Deschatelets, PhD, Lil Edis, PhD, Cedric G Francois, MDPhD, Patrick J Johnson, PhD, Helen J Richardson, Lisa Tan, Carolina A Vega, Jason Lickliter, MBBS,PhD

Blood (2016) 128 (22): 1251.

https://doi.org/10.1182/blood.V128.22.1251.1251

Published: 2016

Journal Articles

The Natural History of Homozygous Cys89Tyr CD59 DefiCiency in Infancy: Differences and Similarities to PNH

Dror Mevorach, MD, Netanel Karbian, Adi Tabib

Blood (2016) 128 (22): 1253.

https://doi.org/10.1182/blood.V128.22.1253.1253

Published: 2016

Journal Articles

Predictors for in-Hospital Mortality in Patients with Autoimmune Thrombotic Thrombocytopenia Purpura (TTP): A Single Center Experience

Huy P. Pham, MD, M.P.H., Wenjing Cao, MD, PhD, Lance A. Williams, MD, Alexander Z. Feldman, MD, Rance C. Siniard, MD, Robin G. Lorenz, MD, PhD, Dheeraj Raju, PhD, Marisa B. Marques, MD, PhD, X. Long Zheng, MD, PhD

Blood (2016) 128 (22): 3853.

https://doi.org/10.1182/blood.V128.22.3853.3853

Published: 2016

Journal Articles

Plasma Levels of Human Neutrophil Peptides and Complement Activation Markers in Patients with Acquired Autoimmune Thrombotic Thrombocytopenic Purpura

Wenjing Cao, MD, PhD, Huy Phu Pham, MD, M.P.H., Lawrence A. Williams, MD, Zheng Ping, MD, PhD, Robin G. Lorenz, MD, PhD, Marisa B. Marques, MD, PhD, X. Long Zheng, MD PhD

Blood (2015) 126 (23): 1147.

https://doi.org/10.1182/blood.V126.23.1147.1147

Published: 2015

Journal Articles

Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease

Ulrich Jaeger, MD, Eileen L Rose, Andrew Singh, Sebastian H A Feickert, Simon Panzer, Bernd Jilma, MD, James C. Gilbert, MD, Sandip Panicker, PhD

Blood (2015) 126 (23): 3560.

https://doi.org/10.1182/blood.V126.23.3560.3560

Published: 2015

Journal Articles

von Willebrand factor is a cofactor in complement regulation

Shuju Feng, Xiaowen Liang, Michael H. Kroll, Dominic W. Chung, Vahid Afshar-Kharghan

Blood (2015) 125 (6): 1034–1037.

https://doi.org/10.1182/blood-2014-06-585430

Published: 2015

Includes: Supplemental data

Journal Articles

Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor

Ellinor I.B. Peerschke, PhD, Sandip Panicker, PhD, Alexa M. Sughroue, James B. Bussel, MD

Blood (2014) 124 (21): 1453.

https://doi.org/10.1182/blood.V124.21.1453.1453

Published: 2014

Journal Articles

Von Willebrand Factor Is a Cofactor in Complement Regulation

Shuju Feng, PhD, Michael H. Kroll, MD, Vahid Afshar-Kharghan, MD

Blood (2014) 124 (21): 109.

https://doi.org/10.1182/blood.V124.21.109.109

Published: 2014

Journal Articles

Complement Activation May Trigger the Onset of Thrombotic Thrombocytopenic Purpura in Patients with Severe ADAMTS13 Deficiency

Xiao-Hui Hu, MD, PhD, Jialing Bao, PhD, Yoshiyasu Ueda, MD, PhD, Takashi Miwa, PhD, Wenchao Song, PhD, X. Long Zheng, MD, PhD

Blood (2014) 124 (21): 600.

https://doi.org/10.1182/blood.V124.21.600.600

Published: 2014

Journal Articles

Plasmin Cleaves Complement iC3b, Preventing CR3/4 Mediated Phagocytosis By Macrophages

Erica A. Peterson, MD, Jonathan H Foley, PhD, Michael J Krisinger, Edward Conway

Blood (2013) 122 (21): 1105.

https://doi.org/10.1182/blood.V122.21.1105.1105

Published: 2013

Journal Articles

The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells

Ching-Chuan Hsieh, Hong-Shiue Chou, Horng-Ren Yang, Feng Lin, Sumantha Bhatt, Jie Qin, Lianfu Wang, John J. Fung, Shiguang Qian, Lina Lu

Blood (2013) 121 (10): 1760–1768.

https://doi.org/10.1182/blood-2012-06-440214

Published: 2013

Includes: Supplemental data

Journal Articles

Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial

Clive S. Zent, MD, Betsy R. LaPlant, Timothy G. Call, MD, Deborah A. Bowen, Michael J. Conte, PA-C, Wei Ding, MD, PhD, George J. Weiner, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 1792.

https://doi.org/10.1182/blood.V120.21.1792.1792

Published: 2012

Journal Articles

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

Antonio M. Risitano, MD, PhD, Patrizia Ricci, Caterina Pascariello, Maddalena Raia, Christoph Q Schmidt, Yingxue Li, Edimara S Reis, Michela Sica, PhD, Rosario Notaro, MD, Luigi Del Vecchio, MD, Fabrizio Pane, Daniel Ricklin, John D Lambris

Blood (2012) 120 (21): 370.

https://doi.org/10.1182/blood.V120.21.370.370

Published: 2012

Journal Articles

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, Michela Sica, Luigi del Vecchio, Christopher J. Horvath, Masha Fridkis-Hareli, Carmine Selleri, Margaret A. Lindorfer, Ronald P. Taylor, Lucio Luzzatto, V. Michael Holers

Blood (2012) 119 (26): 6307–6316.

https://doi.org/10.1182/blood-2011-12-398792

Published: 2012

Includes: Supplemental data

Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers

Blood (2011) 118 (17): 4705–4713.

https://doi.org/10.1182/blood-2011-06-359646

Published: 2011

Includes: Supplemental data

Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD

Blood (2010) 116 (21): 637.

https://doi.org/10.1182/blood.V116.21.637.637

Published: 2010

Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD

Blood (2010) 116 (21): 638.

https://doi.org/10.1182/blood.V116.21.638.638

Published: 2010

Journal Articles

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement

Margaret A. Lindorfer, Andrew W. Pawluczkowycz, Elizabeth M. Peek, Kimberly Hickman, Ronald P. Taylor, Charles J. Parker

Blood (2010) 115 (11): 2283–2291.

https://doi.org/10.1182/blood-2009-09-244285

Published: 2010

Journal Articles

A Novel Approach to Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Both Hemolysis and C3 Deposition Are Blocked by a Monoclonal Antibody (mAb) Specific for the Alternative Pathway of Complement (APC) C3/C5 Convertase.

Ronald P Taylor, PhD, Margaret A Lindorfer, PhD, Andrew W Pawluczkowycz, MS, Charles J Parker, MD

Blood (2009) 114 (22): 157.

https://doi.org/10.1182/blood.V114.22.157.157

Published: 2009

NARROW

Complement Activation in a Murine Model of Sickle Cell Disease: Inhibition of Vaso-Occlusion By Blocking C5 Activation

APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

The Natural History of Homozygous Cys89Tyr CD59 DefiCiency in Infancy: Differences and Similarities to PNH

Predictors for in-Hospital Mortality in Patients with Autoimmune Thrombotic Thrombocytopenia Purpura (TTP): A Single Center Experience

Plasma Levels of Human Neutrophil Peptides and Complement Activation Markers in Patients with Acquired Autoimmune Thrombotic Thrombocytopenic Purpura

Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease

von Willebrand factor is a cofactor in complement regulation

Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor

Von Willebrand Factor Is a Cofactor in Complement Regulation

Complement Activation May Trigger the Onset of Thrombotic Thrombocytopenic Purpura in Patients with Severe ADAMTS13 Deficiency

Plasmin Cleaves Complement iC3b, Preventing CR3/4 Mediated Phagocytosis By Macrophages

The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells

Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial

Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement

A Novel Approach to Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Both Hemolysis and C3 Deposition Are Blocked by a Monoclonal Antibody (mAb) Specific for the Alternative Pathway of Complement (APC) C3/C5 Convertase.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only